Omnicell, Inc. (NASDAQ:OMCL) EVP Robin Gene Seim sold 15,109 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $50.86, for a total transaction of $768,443.74. Following the transaction, the executive vice president now owns 58,144 shares of the company’s stock, valued at $2,957,203.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 0.30% during trading on Wednesday, reaching $50.60. 201,719 shares of the company traded hands. The firm’s 50 day moving average is $45.75 and its 200-day moving average is $41.48. The stock’s market capitalization is $1.90 billion. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $51.97.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. On average, equities research analysts anticipate that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Omnicell, Inc. (OMCL) EVP Sells $768,443.74 in Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/omnicell-inc-omcl-evp-sells-768443-74-in-stock/1496574.html.

A number of analysts recently weighed in on the company. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and issued a $40.00 price objective on shares of Omnicell in a report on Sunday, July 30th. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price objective on shares of Omnicell in a report on Tuesday, July 25th. Craig Hallum increased their price objective on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Dougherty & Co increased their price objective on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, July 28th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $49.00.

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Omnicell during the fourth quarter valued at about $788,000. Norges Bank bought a new position in shares of Omnicell during the fourth quarter worth $10,913,000. UBS Asset Management Americas Inc. increased its position in shares of Omnicell by 9.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 188,158 shares of the company’s stock worth $6,378,000 after buying an additional 15,779 shares during the period. First National Bank of Omaha bought a new position in shares of Omnicell during the first quarter worth $865,000. Finally, Louisiana State Employees Retirement System increased its position in shares of Omnicell by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock worth $614,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 96.35% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.